Advertisement
Advertisement

ACRV

ACRV logo

Acrivon Therapeutics, Inc. Common Stock

1.69
USD
Sponsored
+0.08
+5.31%
Feb 06, 15:58 UTC -5
Closed
exchange

After-Market

1.69

0.00
+0.30%

ACRV Earnings Reports

Positive Surprise Ratio

ACRV beat 10 of 12 last estimates.

83%

Next Report

Date of Next Report
Mar 24, 2026
Estimate for Q4 25 (Revenue/ EPS)
$169.02K
/
-$0.47
Implied change from Q3 25 (Revenue/ EPS)
--
/
--
Implied change from Q4 24 (Revenue/ EPS)
--
/
-21.67%

Acrivon Therapeutics, Inc. Common Stock earnings per share and revenue

On Nov 13, 2025, ACRV reported earnings of -0.47 USD per share (EPS) for Q3 25, beating the estimate of -0.60 USD, resulting in a 21.90% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +8.21% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 10 analysts forecast an EPS of -0.47 USD, with revenue projected to reach 169.02 thousand USD, implying an increase of 0.00% EPS, and -- of --% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Takeda Pharmaceutical Company Limited - ADR
Report Date
Jan 30, 2026 For Q3 26
Estimate
$34.44
Actual
$65.64
Surprise
+90.61%
FAQ
For Q3 2025, Acrivon Therapeutics, Inc. Common Stock reported EPS of -$0.47, beating estimates by 21.9%, and revenue of $0.00, 0% as expectations.
The stock price moved up 8.21%, changed from $2.07 before the earnings release to $2.24 the day after.
The next earning report is scheduled for Mar 24, 2026.
Based on 10 analysts, Acrivon Therapeutics, Inc. Common Stock is expected to report EPS of -$0.47 and revenue of $169.02K for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement